Gary Gelbfish, M.D. Appointed as Observer to the CorMedix’ Board of Directors by Elliott Management
Key Summary: On June 27, 2017, Elliott Associates announced that Dr. Gary Gelbfish has been appointed as a Board Observer to the Board
Market Cap: $27 million| CorMedix Inc. is a pharmaceutical company that in-licenses, develops and commercializes prophylactic and therapeutic products for the treatment of infectious diseases in cardiac, renal and oncology patients.
On February 17, 2015, Elliott Associates disclosed 9.9% stating that it initiated a dialogue with the Management and Board of Directors regarding steps to maximize shareholder value. Source
On June 27, 2017, Elliott Associates disclosed that, based upon discussions between them and the company, Dr. Gary Gelbfish has been appointed as a Board Observer to the Board to attend meetings in a non-voting capacity. Source
Member discussion